Drug Trial Radar · NCT04678830
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Mar 1, 2021
Primary completion
Jun 5, 2021
Study completion Jul 8, 2021
Sponsor
- Lead sponsor
- CytoDyn, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Amarex Clinical Research
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (\> 12 weeks) of COVID-19.
Conditions
- Coronavirus Disease 2019
Interventions
PlacebosDrug
Placebos
Leronlimab (700mg)Drug
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.Time frame: Changes in COVID-19 related symptoms from baseline (start of treatment) and day 56 (end of treatment)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Arthritis & Rheumatic Disease Specialties
Aventura, Florida
Center for Advanced Research & Education (CARE)
Gainesville, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.